Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2024Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJennifer L. CrombieDana-Farber Cancer InstituteMJMonika JunGenmab (United States)TWTongsheng WangAnhui University of Traditional Chinese Medicine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Crombie et al. (2024) studied this question.

synapsesocial.com/papers/68e6023bb6db6435875958dbhttps://doi.org/10.1080/10428194.2024.2371472
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice2022 · 114 citations
  2. 2Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma2023 · 20 citations
  3. 3Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study2022 · 20 citations
  4. 4THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA2022 · 47 citations
  5. 5Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies2020 · 123 citations